3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
25
Colorectal Neoplasms
12
Stomach Neoplasms
10
Neoplasm Metastasis
10
Esophageal Squamous Cell Carcinoma
9
Advanced Solid Tumor
9
Carcinoma, Hepatocellular
7
Advanced Solid Tumors
5
Squamous Cell Carcinoma of Head and Neck
4
Solid Tumor
4
Melanoma
4
Lung Neoplasms
4
Carcinoma, Transitional Cell
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Neoplasms
3
Lymphoma
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Interventions
Fluorouracil
12
pembrolizumab
9
Oxaliplatin
9
Nivolumab
9
Leucovorin
8
Capecitabine
7
Cisplatin
6
Trastuzumab
4
Paclitaxel
3
Drug Therapy
3
Docetaxel
3
zimberelimab
2
zanidatamab
2
tucatinib
2
spartalizumab
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
zolbetuximab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tezacitabine
1
ribociclib
1
quemliclustat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma Of Esophagus
×
tislelizumab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled